Research programme: anti-phosphatidylserine monoclonal antibodies - Peregrine Pharmaceuticals

Drug Profile

Research programme: anti-phosphatidylserine monoclonal antibodies - Peregrine Pharmaceuticals

Alternative Names: 2aG4; Anti-phosphatidylethanolamine monoclonal antibodies - Peregrine; Anti-phospholipid monoclonal antibodies - Peregrine; ch1N11; PGN-502; PGN-503; PGN-504; Truncated tissue factors - Peregrine; Vascular targeting agents - Peregrine

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center
  • Developer Peregrine Pharmaceuticals
  • Class Diagnostic agents; Monoclonal antibodies
  • Mechanism of Action Diagnostic imaging enhancers; Immunostimulants; Magnetic resonance imaging enhancers; Phosphatidylserine receptor antagonists; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 27 Oct 2016 Additional pharmacodynamics data from preclinical studies in Breast cancer released by Peregrine Pharmaceuticals
  • 20 Apr 2016 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) (9194582; 3182644)
  • 29 May 2015 Peregrine Pharmaceutical and Memorial Sloan Kettering Cancer Center enter into a research collaboration to develop phosphatidylserine-targeting agents, including bavituximab, in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top